ERN1 and Miyoshi myopathy: Although the potential of the IRE1α–sXBP1 pathway as a therapeutic target in several types of cancer has been extensively recognized [12], the detailed phenotypes of UPR in the patients with MM and the effects of IRE1α inhibitors on MM remain debatable [4,13].